<u>NOTICE OF CHANGE IN CORPORATE STRUCTURE</u>

Pursuant to Section 4.9 of National Instrument 51-102 –
Continuous Disclosure Obligations

1. Names of parties to the transaction:

Entourage Health Corp. ("**Entourage**" or the "**Company**"), 1001095275 Ontario Inc. (the "**Purchaser**") and 2437653 Ontario Inc. (the "**Guarantor**").

2. Description of the transaction:

On April 4, 2025, the Company completed its previously announced sale to the Purchaser by way of a statutory plan of arrangement under the *Business Corporations Act* (Ontario) (the "**Transaction**"). The Transaction was governed by an arrangement agreement dated December 30, 2024 (the "**Arrangement Agreement**") between the Company, the Purchaser, and the Guarantor. Pursuant to the terms of the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Company (the "**Common Shares**") for cash consideration equal to C$0.005 per Common Share (the "**Consideration**"). Certain obligations of the Purchaser under the Arrangement Agreement were guaranteed by the Guarantor. Each of the Purchaser and the Guarantor are related parties of LiUNA Pension Fund of Central and Eastern Canada. The Arrangement Agreement also provided for the same Consideration to be paid to holders of certain vested deferred share units of the Company. All issued and outstanding options in the capital of the Company were cancelled without any consideration paid to the holders thereof.

In connection with the Transaction, the Company had also entered into debt settlement agreements (the "**Debt Settlement Agreements**") with holders of C$1,013,050 in aggregate principal amount of unsecured debentures issued by a subsidiary of the Company (the "**Unsecured Debentures**"). The Debt Settlement Agreements provided for the full and final settlement of the Unsecured Debentures in exchange for an aggregate cash payment of C$250,000 to the holders of the Unsecured Debentures, which was paid upon closing of the Transaction.

In connection with the Transaction, the Common Shares were delisted from the TSX Venture Exchange at the close of trading on April 8, 2025.

3. Effective date of the transaction:

April 4, 2025

4. Names of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity:

An application to cease to be a reporting issuer in each of the provinces of Canada in which it is a reporting issuer will be filed by Entourage with the Ontario Securities Commission, its principal regulator.

5. Date of the reporting issuer's first financial year-end after the transaction if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:

Not applicable.

6. The periods, including the comparative periods, if any, of the interim financial reports and the annual financial statements required to be filed for the reporting issuer's first financial year after the transaction if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:

Not applicable.

7. The documents that were filed under National Instrument 51-102 that described the transaction and where those documents can be found in electronic format if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:

Not applicable.

DATED April 9, 2025